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ABSTRACT 
Over the last twenty years, evidence has been provided that the plasma membrane is 
partitioned with microdomains, laterally mobile in the bilayer, providing the necessary 
microenvironment to specific membrane proteins for signalling pathways to be 
initiated. We discuss here the importance of such microdomains for Toll-like 
receptors (TLR) localization and function. First, lipid microdomains favour recruitment 
and clustering of the TLR machinery partners, i.e. receptors and co-receptors 
previously identified to be required for ligand recognition and signal transmission. 
Further, the presence of the so-called Cholesterol Recognition Amino-Acid 
Consensus (CRAC) sequences in the intracellular juxtamembrane domain of several 
Toll-like receptors suggests a direct role of cholesterol in the activation process.  
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ABBREVIATIONS 
ABCA1/G1: ATP-binding cassette, sub-family A/G, member 1; AP-1: activator protein 
1; CARC: inverted “CRAC” domain; CD 14/36/55: cluster of differentiation 14/36/55; 
CRAC: Cholesterol Recognition Amino-Acid Consensus sequence; CXCR4: C-X-C 
chemokine receptor type 4; DAMP: danger-Associated Molecular Patterns; ECD: 
extracellular domain; EGF: Epidermal growth factor; EGFR: Epidermal growth factor 
receptor; EtOH: Ethanol; GM-1: monosialotetrahexosylganglioside; GPCR: G 
protein–coupled receptors; GPI: glycosyl phosphoinositol; HsP70/90: 70/90 kilodalton 
heat shock proteins; IFN β/γ: Interferon β/γ;IL-1: Interleukin-1; IRF : Interferon 
regulatory factor; LPS: lipopolysaccharides; LRR: Leucine-rich Repeats; MAL: 
MyD88 adapter-like - also known as TIRAP; MβCD: methyl β- cyclodextrin; MD-2: 
myeloid differentiation protein-2; MPL: Monophosphoryl Lipid A; MyD88 : myeloid 
differentiation factor 88; NF-κB : nuclear factor kappa B; PAMP: Pathogen-
Associated Molecular Patterns; PIP2 or PtdIns(4,5)P2: Phosphatidylinositol 4,5-
bisphosphate; RTK: Receptor tyrosine kinases; SM: sphingomyelin; Src kinase: 
Sarcoma proto-oncogene tyrosine-protein kinase; TIR: toll-interleukin 1 receptor; 
TIRAP: TIR domain containing adaptor protein - also known as MAL; TLR: toll-like 
receptor; TM: transmembrane; TMD: transmembrane domain; TRAM: TRIF-related 
adaptor molecule; TRIF: TIR domain-containing adaptor inducing IFN-β. 
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1 INTRODUCTION 
It has been shown for years that membrane protein activity is modulated by the lipids that 
surround them. Some proteins sense directly the membrane physico-chemical properties such as 
fluidity, polarity, curvature, hydrophobic mismatch, thickness and lateral membrane tension. In 
other cases, specific interactions between defined protein motifs and given lipids have been 
evidenced. Since the seminal hypothesis of a fluid mosaic model membrane [1], an overwhelming 
body of evidence was collected that supports the existence in the membrane of differentiated 
domains characterized by a specific chemical composition. One example of such microdomains is 
the so-called membrane rafts that were proposed to be transient domains enriched in 
sphingolipids, cholesterol and saturated lipids [2,3]. These lipids are laterally mobile in the bilayer, 
leading to changes in lipid bilayer thickness and allowing recruitment of specific proteins [2,3]. It 
has been proposed that lipid microdomains might provide specific membrane proteins with the 
necessary microenvironment for the initiation of signalling pathways [4].  
2 TOLL-LIKE RECEPTORS 
Toll-like receptors (TLRs) are Type I transmembrane receptors in charge of recognition of 
conserved patterns characteristic of bacterial, viral or fungal invasions, but distinguishable from 
host molecules, the so-called Pathogen-Associated Molecular Patterns (PAMPs), and some 
endogenous intracellular molecules or  extracellular matrix components released by activated or 
necrotic cells designed as Danger-Associated Molecular Patterns (DAMPs) [5,6]. They are major 
contributors of the innate immune system of mammalian organisms and their activation induces 
the secretion of pro-inflammatory mediators like cytokines, chemokines, type I interferon (IFN), 
reactive oxygen species, and other mediators. 
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The structure of TLRs is characterized by a N-terminal extracellular domain (ECD) made of 
leucine-rich repeats (LRRs), short motifs that fold into a characteristic solenoid structure giving to 
the ectodomain a horseshoe-shape, a single transmembrane domain, and a C-terminal 
intracellular signalling domain that contains a conserved region called the Toll/IL-1 receptor (TIR) 
domain, characteristic of the Interleukin-1 receptor / toll-like receptor superfamily [7-9].  
 
Human TLR family comprises 10 proteins, each of them being specialized in the recognition of a 
specific class of PAMPs. The most studied Toll-like receptor, TLR4, recognizes bacterial 
lipopolysaccharides of the outer membrane of Gram-negative bacteria, which are responsible for 
most dramatic clinical manifestations of bacterial infections in mammals. TLR1, 2 and 6 recognize 
bacterial and fungal lipoprotein and peptidoglycan; TLR3, TLR7 and 8 recognize respectively viral 
double stranded RNA, single stranded DNA and single stranded RNA while bacterial flagella and 
unmethylated CpG sequences characteristic of bacterial DNA activate TLR5 and TLR9-dependent 
signalling cascades, respectively. The function of human TLR10 is still unclear but seems to 
cooperate with the TLR1/2/6 family [8,10]. 
 
TLRs can be divided into two subgroups, depending on their cellular localization: plasma 
membrane TLRs include TLR1, TLR2, TLR4 and TLR5, while other TLRs (TLR3, TLR7, TLR8 and 
TLR9) localize to and signal from acidified compartments of the endolysosomal pathway. 
 
The signalling cascades induced by Toll-like Receptor ligands can be divided into two main 
cascades depending on the intracellular adaptor molecules they recruit. The myeloid differentiation 
primary response protein 88 (MyD88) is the main adaptor of the first signalling cascade leading to 
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the activation of Nuclear Factor-κB (NF-κB) and Activated Protein-1 (AP-1) transcription factors. 
The second cascade is dependent on the activation of interferon (IFN)-regulatory factors (IRFs) by 
TIR domain-containing adaptor protein inducing IFN-β (TRIF). TLR 1/2/6, 7, 8 and 9 activate 
exclusively the MyD88-dependent pathway (even if growing evidence suggests TLR1/2/6 are also 
capable to activate the second signalling pathway in some conditions). TLR3 activates exclusively 
the TRIF-dependent pathway. TLR4 is generally accepted as the only Toll-like Receptor activating 
both signalling pathways [8,10].  
 
Ligands are recognized by the extracellular domains of TLRs at different binding sites depending 
on the receptor. The overall shape of the signalling TLR-ligand complexes is similar among all 
TLRs and consists in a m-shaped TLR ECD dimer, in which the N-termini stretch out to opposite 
ends and the C-termini interact in the middle. Dimerization of TLR monomers is usually induced by 
ligand recognition (with the exception of TLR7-8 and 9 existing as an inactive homodimer in non-
activated cells, and which will be activated upon ligand binding after cleavage in the endosomes) 
[6,11]. Formation of dimers upon activation supports the hypothesis that dimerization of the ECDs 
enforces dimerization of the intracellular signalling TIR domains, hence able to recruit adaptor 
molecules and trigger downstream signalling pathways [6,11]. 
 
3 LIPID REGULATION OF TOLL-LIKE RECEPTOR ACTIVITY 
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3.1 TLR signalling is initiated in lipid microdomains 
The existence of membrane lipid microdomains, the so-called lipid rafts, has been proposed in the 
nineties by Kai Simons [2]. It is generally accepted that these short-lived (~100ms) microdomains 
are cholesterol and sphingolipids-enriched regulate the biological activity of proteins inserted into 
these lipid domains by influencing the membrane physico-chemical properties or through direct 
binding to proteins. Membrane lipid partitioning may also lead to the formation of multicomponent 
transduction complexes [2] and explain the spatial segregation of certain signalling pathways 
emanating from the cell surface [3].  
3.1.1 Role of cholesterol 
 First, it was shown that cholesterol loading of macrophage plasma or endosomal 
membranes enhanced the inflammatory activity of TLR4 and 3 agonists [12]. More convincingly, 
depletion of cholesterol or disruption of lipid rafts by different drugs downregulate the inflammatory 
signalling. The treatment with the cholesterol depleting agent, methyl β-cyclodextrin (MβCD), 
causes a decrease of the NF-κB recruitment into nucleus or a decreased activity of the MyD88-
dependent pathway [13-18]. Furthermore, depletion of cholesterol using, statins or α-tocopherol 
derivatives [14,16,19,20] confirmed the importance of cholesterol-rich domains in TLR initiation. 
Ethanol, on its turn, modulates TLR4 activation mechanism by LPS by mimicking the raft-
disrupting agents streptolysin-O or saponin, hence affecting TLR4 partitioning into rafts after LPS 
stimulation [16,21,22].  Similarly, the down-regulating effect of surfactants or oxidized 
phospholipids on LPS activation was correlated to a decreased TLR4 translocation into lipid rafts 
[23,24] while neither LPS binding nor TLR4 surface expression were reduced.  
 Finally, macrophages from mice lacking the cholesterol efflux pump ATP-binding cassette 
subfamily A1 (ABCA1) presented an enhanced proinflammatory response to LPS [25]. It was 
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further demonstrated that this deficiency cause an accumulation of free cholesterol within lipid 
rafts and localization of TLRs into rafts explaining the enhanced activation of MyD88-dependent 
signalling pathways by TLR4, 2, 7 and 9 [26]. Modification of lipid rafts by treatment with MβCD or 
nystatin corrected the abnormal hyper-responsiveness of ABCA1 mutants to LPS [27]. Similar 
results were obtained with ABCA1 and ABCG1 double mutants, presenting a hyper-
responsiveness to TLR2, 3 and 4, but not TLR 7 or 9 agonists which was abolished following 
treatment with MβCD or filipin [28]. 
 
3.1.2 Role of sphingomyelin 
Recruitment of TLR4/MD2 upon LPS stimulation decreases in mutants for sphingomyelin 
synthases SMS1 and SMS2 (responsible for the synthesis of sphingomyelin from ceramide and 
phosphatidylcholine) [29-31]. As a consequence, NF-κB activation by LPS in these mutants was 
attenuated. Similarly, a partial deficiency in the Serine Palmitoyl-CoA Transferase (SPT) - the key 
enzyme of the de novo biosynthetic pathway of sphingolipids - also resulted in a reduced 
recruitment of TLR4/MD2 on cell surface and decreased NF-κB activation upon LPS stimulation 
[32]. It should be noted however that SPT deficiency was linked to an increase of ABCA1 and 
ABCG1 cell surface expression, increasing the cholesterol efflux, which means that SPT 
deficiency affects both sphingomyelin synthesis and cholesterol accumulation into plasma 
membrane. Moreover, macrophages depleted in sphingomyelin presented attenuated LPS 
responses [30,33,34].  
Finally, one should note that LPS stimulation is followed by a rapid production of ceramide 
(resulting from sphingomyelin hydrolysis by the neutral or acid sphingomyelinase), apparently 
crucial for LPS activity since inhibition of the sphingomyelinase blocks signalling events [33,35,36]. 
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Similarly to TLR4, TLR3 activation up-regulates genes involved in sphingolipid metabolism and 
increases sphingomyelin and ceramide lipid contents [37]. 
 
3.1.3 Importance of lipid partitioning for the formation of “activation clusters” 
TLR4 is not detected in lipid raft-enriched fractions isolated from non-activated cells but is 
recruited in GM-1 ganglioside (a raft associated lipid) and CD14 enriched fractions, after LPS 
stimulation [14]. This leads to the concept that TLR activation requires the formation of 
“supramolecular activation clusters” [38,39] within lipid raft microdomains, offering a platform that 
brings receptor molecules close together, allowing their activation and signal transduction [40,41]. 
Such assemblies have been characterized by confocal microscopy or fluorescence resonance 
transfer (FRET) between raft constituents, co-receptors and TLR4 [14,42,42,43], affinity 
chromatography or peptide-mass fingerprinting experiments [42,44-46]. The role of these raft-
associated TLR4 activation cluster proteins has been largely discussed [47] and we will focus here 
on CD14 and CD36, the two main raft-associated co-receptors of TLR2 and 4.  
Apart from the membrane co-receptors, intracellular co-adaptors for TLR signalling cascades are 
also associated to lipid microdomains: MAL (also known as TIRAP), the co-adaptor of MyD88, and 
the co-adaptor for TRIF, TRAM (TRIF-related adaptor molecule). Here again, it was suggested 
that lipid rafts favour the increased density of lipid-associated adaptor molecules at the site of 
TLR4 clustering, as evidenced by the increased TLR4 clustering and signalling following 
stabilization of lipid rafts with cholera toxin B (binding GM-1 in lipid raft microdomains)[48].  
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3.1.3.1 CD14  
The Cluster of Differentiation CD14 exists in two forms, one expressed on the cell surface thanks 
to a glycosylphosphatidylinositol anchor (mCD14) and a soluble form found in the serum 
(sCD14)[49,50]. Both forms were shown to facilitate LPS recognition by the TLR4/MD-2 complex, 
but most studies have focused on deciphering the role of the membrane form in the LPS 
machinery. After LPS binding, mCD14 transfers LPS to the TLR4/MD-2 complex which dimerizes 
and triggers the MyD88-dependent pathway and the resulting secretion of pro-inflammatory 
cytokines [38,51]. Once the MyD88-pathway cascade has been triggered, the TLR4/MD-2/LPS 
complex is endocyted and activates the TRIF-dependent production of type I interferons [50,52].  
 
CD14 greatly enhances the detection of LPS by TLR4 but its requirement depends also on the 
LPS phenotype or structure: although CD14 is required for the detection of smooth LPS (LPS with 
abundant O-glycosylation, the more common phenotype of LPS), it is not required by rough LPS 
(LPS lacking the O-antigen), MPL (Monophosphoryl Lipid A) and CRX-527 to activate the MyD88-
dependent pathway [53-56]. 
 Thanks to its GPI anchor, mCD14 is localized in the cholesterol- and sphingolipid-rich 
microdomains of the plasma membrane [14,57] and is essential for the TLR4/MD-2 recruitment 
into lipid microdomains, a process required for efficient dimer formation [58]. This role was further 
confirmed by deciphering the anti-inflammatory activity of a cationic lipid (lipofectamine) on the 
LPS-induced activation of TLR4: this lipid was shown to uncouple LPS binding by preventing 
CD14-TLR4 interactions [59]. The same hypothesis has been formulated for EtOH effect, altering 
LPS-related partition of CD14 [16]. It is also believed to be the main mechanism of modulation of 
immune cascades by oxidized phospholipids [60]. 
  
12 
 
 The higher hydrophobicity of rough LPS, MPL and CRX-527, as compared to smooth LPS 
phenotype, allows a better incorporation of these ligands into biological membranes and enhanced 
mobility, and may therefore explain the non-requirement of mCD14 for activating the MyD88-
dependent pathway [53,54]. Importance of membrane insertion of LPS has been highlighted by 
several studies using model membranes or giant liposomes, showing a preferential incorporation 
of LPS into sphingomyelin and cholesterol-rich domains [61-63] and the ability of rough LPS, as 
compared to smooth form, to induce the formation of lipid microdomains into model membranes 
[64,65]. 
 However, LPS is unable to activate the TRIF-dependent pathway in macrophages 
expressing a truncated inactive variant of CD14, irrespectively of the LPS phenotype [53]. Since 
CD14 controls the LPS-induced endocytosis of the activated TLR4 [66], which is required for the 
activation of the TRIF-dependent pathway [52], it is generally accepted that CD14 also controls the 
internalization of the TLR4/MD-2/LPS complex required to induce the TRIF-dependent pathway 
[50,66]. This role has been confirmed by forcing endocytosis of LPS, using latex beads or cationic 
liposomes, in the absence of CD14 [66-68]. 
Clathrin-mediated endocytosis is believed to be the principal endocytic process [52,69,70] but 
blocking of this specific endocytic pathway using potassium depletion and Dynasore treatment did 
not inhibit completely the internalization of membrane TLR4 upon LPS stimulation. Interestingly, 
this specific internalization of membrane TLR4 could be abrogated by depletion of plasma 
membrane cholesterol with MβCD [69]. Therefore the role of lipid-raft or caveolin-dependent 
mediated endocytosis has emerged [69,71-73].  
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Apart from TLR4 signalling, CD14 is also a co-receptor for TLR2, TLR3, TLR7 and TLR9 [74] and 
its role in the re-location of TLR2 into lipid rafts, formation of the TLR2/ligand complex and 
subsequent activation is well documented [75-77].  
3.1.3.2 CD36 
CD36, a member of the class B scavenger receptor family, acts as a co-receptor for TLR2 [40,78-
81] but also for a non-canonical TLR4/TLR6 heterodimer [82]. CD36 is a membrane protein, found 
in lipid microdomains, and which is thought to adopt a hairpin-like structure with palmitoylated 
cytoplasmic C and N terminal tails [83,84]. Similarly to CD14, it has been suggested that the role 
of CD36 is to recruit TLR1/TLR2 heterodimers into lipid rafts upon stimulation [40]. CD36 is also 
involved in endocytic uptake of different components including oxidized LDL [85] amyloid β peptide 
[86], and possibly LPS [87], which are all activators of TLR4 or TLR2-dependent cascades. This 
suggests that CD36, similarly to CD14, also regulates internalization of TLRs. Indeed, TLR2/6 and 
CD36 co-localized intracellularly following activation with TLR2 ligands and this localization was 
prevented by treatment with either filipin or nystatin [40]. Similarly, CD36, TLR4 and TLR6 co-
localized in intracellular compartments following treatment with oxLDL and inhibition of dynamin-
dependent endocytosis blocked CD36-TLR4-TLR6 signalling induced by oxidized LDL[82].  
3.1.3.3 MAL 
The adaptor protein MAL (TIRAP) contains a N-terminal phosphatidylinositol-4,5-bisphosphate 
(PtdIns(4,5)P2 or PIP2) binding motif, rich in positively-charged lysine residues [88]. Thanks to this 
anchor, MAL is pre-localized into raft lipid microdomains enriched with PtdIns(4,5)P2 [88]. The 
recruitment of TLRs into rafts would therefore favour the interactions with MAL and MyD88 TIR 
domains, which is a prerequisite for the induction of the signalling pathway.  
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3.1.3.4 TRAM 
Similarly to MAL, the adaptor protein TRAM is localized in the plasma membrane. TRAM contains 
a N-terminal myristoylation site, similar to that found in mammalian Src kinases, which is modified 
by the addition of a myristoyl group on a specific glycine residue. Myristoylation of TRAM allows its 
association with the membrane (most probably into lipid microdomains enriched in saturated acyl 
chain lipids) but is probably not sufficient to confer stable membrane binding. It was suggested 
that several lysine residues close to the myristoylation site may serve as a polybasic cluster 
stabilizing membrane binding by electrostatic interactions with phospholipid head groups of the 
lipid membrane [89]. Mutation of this myristoylation site leads to improper localization of TRAM 
and affects the TLR4-dependent LPS response [89].  
 
3.2 Lipid-binding sequences within TLRs 
TLR dimerization process (required for activation of the TLR1 to TLR6) is believed to be 
dependent on both ectodomains (sufficient to form in vitro dimers after ligand recognition) and 
transmembrane regions [90]. Isolated transmembrane domains have indeed a strong tendency to 
oligomerize [91,92] in a homotypic manner. Heterotypic interactions of transmembrane domains 
from different TLR showed a preference for their native dimer partners (i.e. TLR2 transmembrane 
domain heterodimerize with TLR1, TLR6 or TLR10 TMDs but not with TLR4 or TLR5) providing 
evidence of specific transmembrane domain interactions [91]. Since truncation of the TLR4 
ectodomain leads to constitutive activation after dimerization of the transmembrane and TIR 
domains, it was proposed that ectodomain exerts an autoinhibitory effect to prevent spontaneous, 
ligand-independent dimerization [93].  
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 Upon activation, TLRs migrate to specific lipid microdomains where they are activated 
and able to transmit signals [14,40,94]. It is likely that the transmembrane region and/or the 
regions surrounding this sequence are involved in the localization of TLRs. It was demonstrated 
indeed that the intracellular localization of TLR9 and TLR7 are governed by their transmembrane 
domains [95,96] and that the localization of TLR3 depends on the juxtamembrane domain [96].  
 Specific amino acid sequences have been associated with the localization of proteins 
within membrane lipid microdomains [97,98]. The presence of a (or several) Cholesterol 
Recognition Amino-Acid Consensus (CRAC) sequence and its counterparts, the CARC sequence, 
in or near the transmembrane region is considered as indicative of cholesterol dependency for 
efficient protein function [99,100]. 
3.2.1 CRAC domains 
The sequence analysis of human Toll-like receptors reveals the presence of CRAC (defined as -
[LV]-X(1,5)-Y-X(1,5)-[RK]-) and/or CARC sequences (defined as -[RK]-X(1,5)-Y-X(1,5)-[LV]-) in the 
cytoplasmic domain close to the transmembrane region (see Table 1a). 
Although most TLRs (with the exception of TLR5 and TLR9) show CRAC-like (or CARC) 
sequences located close to their transmembrane domain, only TLR2, TLR4, TLR7 and TLR8 
possess both CRAC and CARC sequences. Interestingly, CARC-CRAC-CARC domains into TLR4 
are located close to the membrane, before the TIR domain. This strongly suggests that this 
intracellular region of TLR4 binds specifically cholesterol. This region corresponds to a sequence 
previously identified as a small hydrophobic segment adjacent to the transmembrane region and 
the TIR domain with the consensus sequence FYFHLxLxxGC among mammalian species (see 
Table 1b) which was demonstrated to be required for both activation and dimerization of TLR4 
[101].  
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 It is likely that the increased bilayer thickness of the lipid bilayer in rafts (due to the high 
content of saturated acyl chain lipids) favours the insertion of the first CARC motif into lipid bilayer 
membrane, and its interaction with cholesterol will lead to structural rearrangements required for 
an efficient activation. The presence of CRAC motifs in TLR4, and the fact that cholesterol is 
required for activation, suggests the interaction of this region with the membrane (and more 
specifically the cholesterol) occurs upon activation and is required for efficient dimerization of the 
receptors. 
 Toll-like receptors belongs to the family of Type-I transmembrane receptors which 
includes receptor tyrosine kinases (RTKs) which are activated by ligand-induced dimerization of 
the receptors [102,103]. The most studied RTK is the Epidermal Growth Factor (EGF) Receptor 
(EGFR) which dimerizes upon recognition of EGF inducing a dramatic conformational change in 
both ectodomains and juxtamembrane regions [102,104,105]. Moreover, EGFR has been also 
found to be inserted into lipid rafts [104,106] and was reported to be regulated by gangliosides 
[107-110] (a specific type of glycosphingolipid located in lipid rafts), as suggested for TLR2 and 
TLR4 [111-113] reinforcing the structural and functional similarities between TLRs and EGFR.  
 The juxtamembrane cytosolic sequence of EGFR contains several basic amino acids 
which are sequestered in the membrane by interacting with anionic phospholipid head groups in 
the inactive conformation. Upon activation, several residues of two EGFR molecules (in an active 
dimeric complex) are pulled out of the plasma membrane and reassemble as antiparallel α-helices 
with a kinase activity. Based on this mechanism, it is likely that cytosolic juxtamembrane 
sequences of the TLRs interact with the membrane [6].  
3.2.2 Sphingolipid domains  
Similarly to cholesterol, sphingolipids are major components of lipid microdomains. A signature 
sequence to be found into the transmembrane domains has been defined recently [97]. The 
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sequence analysis of human Toll-like receptors reveals the presence of sphingolipid binding-like 
sequences in the transmembrane region of TLR3 and TLR5 (see Table 2). Interestingly, TLR3 
which presents a CARC motif in the juxtamembrane segments close to the membrane (possibly 
inserted into membrane bilayer in raft microdomains) also presents two successive sphingolipid 
binding-like motifs in its transmembrane segment. Such coexistence of both specific sequences 
has not been reported earlier and strongly suggests that TLR3 interacts with both sphingolipids 
and cholesterol. This is in line with the fact that cholesterol accumulation into rafts enhances TLR3 
activation (see 3.1.1) and that TLR3 activation upregulates sphingolipid metabolism (see 3.1.2).  
4 CONCLUSIONS 
Although compelling evidences demonstrate that Toll-like Receptor signalling depends on the lipid 
membrane composition, little is known about the mechanism by which lipid composition influence 
TLR activity. 
It has been proposed that lipid microdomains favour clustering of the TLR activation complexes 
i.e. TLR and co-receptors like CD14 or CD36. Upon ligand recognition, all co-receptors migrate 
into rafts, bringing TLRs in close proximity thereby allowing TLR dimerization and activation. 
Since CRAC and CARC domains are located into the juxtamembrane domain of TLR4, it can be 
suggested that, upon ligand recognition and recruitment into lipid microdomains (with the help of 
CD14 or another co-receptor), a structural rearrangement occurs allowing the insertion of the first 
CARC motif of the juxtamembrane segment of TLR4 region into the transmembrane stretch 
(Figure 1 - upper panel). This rearrangement would bring the TIR domain closer to the membrane 
in a way it interacts with MAL (associated to the membrane thanks to its PIP2 anchor) and initiates 
the signalling cascade [114].  After insertion into the lipid bilayer, the juxtamembrane segment 
would adopt an alpha-helix secondary structure (as predicted by secondary prediction programs), 
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extending the existing transmembrane helix (Figure 1 - lower panel). This helix would rigidify the 
juxtamembrane segment, stabilize the TIR domains and favour the formation of TIR/TIR dimers. 
This is in agreement with previous statements that the cytosolic juxtamembrane domain has 
rotational flexibility thanks to the presence of several glycine residues able to adopt a wider range 
of dihedral angles [115].  
 
Figure 1: Activation of TLR4 before and after stimulation by bacterial lipopolysaccharides 
(LPS). Inactive TLR4s exist as monomers in lipid membranes before stimulation and are recruited 
into lipid microdomains upon stimulation. Upper panel shows the sequence of human TLR4 (622-
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687) and respective CARC and CRAC domains. Lower panel is a schematic view of the activation 
process (shown for the MyD88-dependent pathway only). Due to membrane thickness increase in 
the raft domains, part of the juxtamembrane domain (in red) containing a CARC sequence adopts 
a helical structure upon insertion into the lipid bilayer. This leads to a shortening of the cytosolic 
juxtamembrane region and allows TIR domain to get closer to the membrane, and to interact with 
membrane-associated co-receptors like MAL, initiating the MyD88-dependent signalling cascades. 
It may also suggest that a rotation of the long helix made of TLR4 transmembrane domain (in 
blue) and part of the juxtamembrane domain (red) would significantly modify the orientation of the 
cytosolic TIR domains with respect to each other. 
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Protein Ref. 
Uniprot 
Residue 
Numbers 
 
                                   Transmembrane  domain 
TLR1 Q15399 546-645 VLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSG 
 
TLR2 O60603 554-653 VLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAY 
                                                                                   *********     ***  
TLR3 O15455 670-769 ELSSHYLCNTPPHYHGFPVRLFDTSSCKDSAPFELFFMINTSILLIFIFIVLLIHFEGWRISFYWNVSVHRVLGFKEIDRQTEQFEYAAYIIHAYKDKDW 
                                                           ********** 
TLR4 O00206 597-696 QRQLLVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNL 
                                                        *********       **********    
TLR5 O60602 605-704 PADIYCVYPDSFSGVSLFSLSTEGCDEEEVLKSLKFSLFIVCTVTLTLFLMTILTVTKFRGFCFICYKTAQRLVFKDHPQGTEPDMYKYDAYLCFSSKDF 
 
TLR6 Q9Y2C9 551-650 VLEGWPDSYKCDYPESYRGSPLKDFHMSELSCNITLLIVTIGATMLVLAVTVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSE  
 
TLR7 Q9NYK1 805-904 IPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNLILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTKDPAV 
                                                                      ********** 
TLR8 Q9NR97 793-892 VKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITTMVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTFYDAYISYDTKDAS   
                                                                        ********* 
TLR9 Q9NR96 784-883 LPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAV  
 
TLR10 Q9BXR5 543-642 MMVGWSDSYTCEYPLNLRGTRLKDVHLHELSCNTALLIVTIVVIMLVLGLAVAFCCLHFDLPWYLRMLGQCTQTWHRVRKTTQEQLKRNVRFHAFISYSE  
 
 
Table 1a. The regions surrounding transmembrane domains are represented here for each human TLR. CRAC sequence defined 
as -[LV]-X(1,5)-Y-X(1,5)-[RK]- [100] is annotated by orange highlighted and underlined characters in the sequences while CARC 
corresponding to the CRAC inverted sequence i.e. -[RK]-X(1,5)-Y-X(1,5)-[LV]- [100], is represented by stars below characters and 
green highlighted sequence. Predicted transmembrane region is represented in dark blue bold and blue highlighted characters.  
  
 
 
TLR4 Ref. 
Uniprot 
Residue 
Numbers 
 
        Transmembrane  domain      
                                 FYFHLxLxxGC 
Human O00206 624-705 NITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       ********** 
Mouse Q9QUK6 622-703 NSTCYMYKTIISVSVVSVIVVSTVAFLIYHFYFHLILIAGCKKYSRGESIYDAFVIYSSQNEDWVRNELVKNLEEGVPRFHL 
                                             **********   
Cow Q6WCD5 625-706 NATCQLSKTIISVSVVTVLLVSVVGVLVYKFYFHLMLLAGCKKYGRGESTYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       ********** 
Pig Q68Y56 625-706 NATCQISEAVISASVLTFLLVSVAGILVYKFYFHLLLFVGCKKYGRGESTYDAFVIYSSQDEDWVRNELVKNLEEGVPPFHL 
                             ********        ********** 
Gorilla Q8SPE8 622-703 NITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENVYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       ********** 
Horse Q9MYW3 626-707 NATCQISKTIVGGSVFSILMVSVIAVLVYKFYFHLMLLAGCKKYGRGESIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       **********      
Dog F1PDB9 625-706 NATCQRSKTIISVSVFTVLMVSLVAVLAYKFYFHLMLLAGCKRYNRGESTYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       **********   
Cat P58727 625-706 NATCQVRKTIITGSVFTVLLVFLVVVLVYKFYFHLMLLAGCKKYSRGESTYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQL 
                             *********       ********** 
 
Table 1b. The regions in TLR4 from different species, surrounding transmembrane domains, are represented here. CRAC 
sequence defined as -[LV]-X(1,5)-Y-X(1,5)-[RK]- [100] is annotated by orange highlighted and underlined characters in the 
sequences while CARC corresponding to the CRAC inverted sequence i.e. -[RK]-X(1,5)-Y-X(1,5)-[LV]- [100], is represented by 
stars below characters and green highlighted sequence. Predicted transmembrane region is represented in dark blue bold and blue 
highlighted characters. 
  
  
 
 
Protein Ref. 
Uniprot 
Residue 
Numbers 
 
                                   Transmembrane  domain 
TLR1 Q15399 546-645 VLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSLCSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSG 
                 
TLR2 O60603 554-653 VLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFLLILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAY 
 
TLR3 O15455 670-769 ELSSHYLCNTPPHYHGFPVRLFDTSSCKDSAPFELFFMINTSILLIFIFIVLLIHFEGWRISFYWNVSVHRVLGFKEIDRQTEQFEYAAYIIHAYKDKDW 
                                                            
TLR4 O00206 597-696 QRQLLVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLMLLAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNL 
                                                        
TLR5 O60602 605-704 PADIYCVYPDSFSGVSLFSLSTEGCDEEEVLKSLKFSLFIVCTVTLTLFLMTILTVTKFRGFCFICYKTAQRLVFKDHPQGTEPDMYKYDAYLCFSSKDF 
 
TLR6 Q9Y2C9 551-650 VLEGWPDSYKCDYPESYRGSPLKDFHMSELSCNITLLIVTIGATMLVLAVTVTSLCIYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSE  
                                                    
TLR7 Q9NYK1 805-904 IPYLATDVTCVGPGAHKGQSVISLDLYTCELDLTNLILFSLSISVSLFLMVMMTASHLYFWDVWYIYHFCKAKIKGYQRLISPDCCYDAFIVYDTKDPAV 
                                                                       
TLR8 Q9NR97 793-892 VKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTAVILFFFTFFITTMVMLAALAHHLFYWDVWFIYNVCLAKVKGYRSLSTSQTFYDAYISYDTKDAS   
                                                                         
TLR9 Q9NR96 784-883 LPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAV  
 
TLR10 Q9BXR5 543-642 MMVGWSDSYTCEYPLNLRGTRLKDVHLHELSCNTALLIVTIVVIMLVLGLAVAFCCLHFDLPWYLRMLGQCTQTWHRVRKTTQEQLKRNVRFHAFISYSE  
 
 
Table 2. The regions surrounding transmembrane domains are represented here for each human TLR. Sphingo-specific lipid 
binding region is defined as -[VITL]-X-X-[VITL]-[VITL]-X-X-[VITL]-[YFW]- [97] and is represented by grey highlighted underlined 
characters. Predicted transmembrane region is represented in dark blue bold and blue highlighted characters. 
